Taro Says FDA Approves Psoriasis Treatment Spray
Taro Pharmaceutical Industries Ltd. said Friday the Food and Drug Administration approved its Topicort spray as a treatment for plaque psoriasis.
The company said Topicort, or desoximetasone, is approved for patients age 18 and older. Taro said U.S. consumers spend about $100 million per year on corticosteroid sprays.
Taro shares gained a penny to $57.98 Friday.